Editorial Staff

Alzheimer Breakthrough Disillusionment: Confusion on FDA’s Approval of Expensive and Possibly Ineffective Drug

/in , , , /by Editorial Staff
Share on Facebook
Share on Twitter
Share on
LinkedIn
+

Hubwonk host Joe Selvaggi talks with precision medicine expert Hannah Mamuszka and Pioneer Institute’s Bill Smith about the promises and pitfalls of the newly approved Alzheimer’s drug Aduhelm, and the challenges presented when new, expensive drugs of dubious benefit are introduced to the nation’s formulary.

Guest:

Hannah Mamuszka is Founder & CEO of ALVA10, a healthcare technology firm. Hannah has spent her 20+ year career in diagnostics – both in pharma and at diagnostics companies, in the lab and on the business side. She believes that the challenges of diagnostic technology fully impacting patient care are more commercial than technical, and conceived of ALVA10 to create a mechanism to pull technology into healthcare by aligning incentives through data. She regularly speaks on issues regarding advancement of technology in healthcare, is on the Board of Directors for two diagnostic companies and writes a column on the value of diagnostics for the Journal of Precision Medicine.

Guest Host:

Dr. William S. Smith is Pioneer’s Visiting Fellow in the Life Sciences. Dr. Smith has 25 years of experience in government and in corporate roles. His career includes senior staff positions for the Republican House leadership on Capitol Hill, the White House Office of National Drug Control Policy, and the Massachusetts Governor’s office where he served under Governors Weld and Cellucci. He spent ten years at Pfizer Inc as Vice President of Public Affairs and Policy where he was responsible for Pfizer’s corporate strategies for the U.S. policy environment. He later served as a consultant to major pharmaceutical, biotechnology and medical device companies. Dr. Smith earned his PhD in political science with distinction at The Catholic University of America.

Get new episodes of Hubwonk in your inbox!

Recent episodes:

Sweden’s Pandemic Paradigm: Does Trust in Citizenry Save Lives

Joe Selvaggi talks with Johan Norberg, author and senior fellow at CATO Institute, about his analysis of Sweden’s resistance to government-mandated COVID-19 control measures, as well as Sweden’s public health outcomes relative to the U.S and peer nations.

Breast Cancer Risk: Testing to Tailored Screening, Treatment, and Prevention

Joe Selvaggi talks with precision medicine expert, Alva 10 CEO Hannah Mamuszka about how individualized testing can both detect and substantially reduce the incidence of breast cancer, a disease that accounts for more than 40k deaths each year.

Landlord’s Foreseeable Duty: Who Is Liable When Crime Lands on the Doorstep?

Joe Selvaggi talks with retired Federal Judge Frank Bailey, president of Pioneer Public Interest Law Center, about the Massachusetts Supreme Judicial Court's decision in Hill-Junious v. UTP Realty, LLC, regarding the limits of liability for a landlord when a murder occurs near her tenant’s location, and the challenges facing small entrepreneurs in high-crime communities.

Trump’s Trial’s Tribulations: Legal Merits of Four Federal Felony Fraud Indictments

Joe Selvaggi talks with legal scholar and George Mason University professor Ilya Somin about the legal merits of the federal indictments against former President Donald Trump and what is likely to come next in the legal proceedings against him and other defendants in the cases involving the aftermath of the 2020 presidential election.

Black Box Budget: Late, Loaded, and Lacking Transparency

Joe Selvaggi talks with Pioneer Institute’s Senior Fellow in Economic Opportunity Eileen McAnneny about the features and flaws of the recently passed 2024 Massachusetts state budget now waiting for Governor Healey’s approval.

Sabotaging Strategic Success: How Price Controls Could Imperil U.S. Pharma Industry

Joe Selvaggi talks with Pioneer Institute’s Director of Life Sciences Initiative Dr. Bill Smith about the policies that drove biopharmaceutical company from Europe to the U.S., and how proposed, similar price controls in President Biden’s Fair Prices Act could distort incentives away from innovation and threaten the success of a thriving and vital U.S. industry.

Local Elections Matter: City Governance Driven by Those Who Show Up

Joe Selvaggi talks with Suffolk County Assistant District Attorney and candidate for Boston City Council’s 8th District Montez Haywood about the city council’s role in local governance and the salient issues at stake in the July 25 special election.

Diagnosing Debilitating Debt: Are We Undertaxing or Overspending?

Joe Selvaggi talks with Cato Institute’s Director of Tax Policies, Dr. Adam Michell about the sources of recent record levels of deficits and debt to understand a policy path toward fiscal sustainability that is politically viable.

Court Compels Colorblindness: Harvard Told No Exceptions for Equality Under Law

Joe Selvaggi speaks with Thomas A. Berry of Cato Institute about the Supreme Court’s ruling in Students for Fair Admissions Inc. v. President & Fellows of Harvard College, its impact on affirmative action, and what comes next for colleges seeking to ensure diverse enrollments.

Baking Young Minds: Scientific Concerns for Cannabis on Kids

Joe Selvaggi talks with professor of psychiatry Dr. Ryan Sultan about the findings of his recently released study on the effects of cannabis on the mental health of American adolescents. Dr. Sultan’s work shows a substantial correlation between cannabis use and negative mental health outcomes.